Analysis of Pharmacotherapy of Arterial Hypertension in Multimorbid Patients
https://doi.org/10.52420/umj.24.1.7
EDN: BOTFNT
Abstract
Introduction. Arterial hypertension (AH) is the most common chronic non-communicable disease, especially among individuals over 60 years old, where its prevalence exceeds 60%. The relationship between blood pressure (BP) levels and the risk of cardiovascular events is observed across all age groups. The aim of the study was to assess the adequacy of antihypertensive therapy in outpatient multimorbid patients of different age groups.
Materials and methods. The study included 323 outpatient patients with verified AH (92 men and 231 women). Patients were divided into three age groups: middle-aged, elderly, and old age. The frequency of achieving target BP levels, the structure of antihypertensive therapy, and the prescription of lipid-lowering and antiplatelet agents were evaluated.
Results. The severity of AH did not differ between the groups. In the elderly groups, patients with high cardiovascular risk and comorbidities such as type 2 diabetes and osteoarthritis predominated. The most frequently prescribed medications were inhibitors of the renin-angiotensin-aldosterone system (94.1%). Target BP levels were mainly achieved due to systolic pressure (60%), while diastolic pressure was only controlled in 22% of cases.
Discussion. The results are consistent with previous studies.
Conclusion. AH in elderly patients is associated with high comorbidity and cardiovascular risk. Achieving target BP levels is possible with combination therapy, including renin-angiotensin-aldosterone system blockers and calcium antagonists. Additional treatment strategies are needed to reduce the residual risk of cardiovascular diseases.
About the Authors
N. V. Izmozherova
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Nadezhda V. Izmozherova — Doctor of Sciences (Medicine), Associate Professor, Head of the Department of Pharmacology and Clinical Pharmacology, Director of the Institute of Clinical Pharmacology and Pharmacy
Ekaterinburg
Competing Interests:
Nadezhda V. Izmozherova and Artem A. Popov are an editorial board members of Ural Medical Journal, and they did not participate in reviewing the material or making a decision about its publication. The other authors declare the absence of obvious or potential conflicts of interest.
A. A. Popov
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Artem A. Popov — Doctor of Sciences (Medicine), Associate Professor, Head of the Department of Hospital Therapy, Institute of Clinical Medicine
Ekaterinburg
Competing Interests:
Nadezhda V. Izmozherova and Artem A. Popov are an editorial board members of Ural Medical Journal, and they did not participate in reviewing the material or making a decision about its publication. The other authors declare the absence of obvious or potential conflicts of interest.
A. A. Kuryndina
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Anna A. Kuryndina — Candidate of Sciences (Medicine), Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Institute of Clinical Pharmacology and Pharmacy
Ekaterinburg
Competing Interests:
Nadezhda V. Izmozherova and Artem A. Popov are an editorial board members of Ural Medical Journal, and they did not participate in reviewing the material or making a decision about its publication. The other authors declare the absence of obvious or potential conflicts of interest.
E. I. Gavrilova
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Elena I. Gavrilova — Candidate of Sciences (Medicine), Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Institute of Clinical Pharmacology and Pharmacy
Ekaterinburg
Competing Interests:
Nadezhda V. Izmozherova and Artem A. Popov are an editorial board members of Ural Medical Journal, and they did not participate in reviewing the material or making a decision about its publication. The other authors declare the absence of obvious or potential conflicts of interest.
M. A. Shambatov
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Muraz A. Shambatov — Candidate of Sciences (Medicine), Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Institute of Clinical Pharmacology and Pharmacy
Ekaterinburg
Competing Interests:
Nadezhda V. Izmozherova and Artem A. Popov are an editorial board members of Ural Medical Journal, and they did not participate in reviewing the material or making a decision about its publication. The other authors declare the absence of obvious or potential conflicts of interest.
V. M. Bakhtin
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Viktor M. Bakhtin — Candidate of Sciences (Medicine), Assistant of the Department of Pharmacology and Clinical Pharmacology, Institute of Clinical Pharmacology and Pharmacy
Ekaterinburg
Competing Interests:
Nadezhda V. Izmozherova and Artem A. Popov are an editorial board members of Ural Medical Journal, and they did not participate in reviewing the material or making a decision about its publication. The other authors declare the absence of obvious or potential conflicts of interest.
References
1. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiologia Polska. 2019;77(2):71–159. DOI: https://doi.org/10.5603/KP.2019.0018.
2. Ostroumova OD, Kochetkov AI, Cherniaeva MS. Arterial hypertension in older adults in the light of new European Guidelines 2018. Rational Pharmacotherapy in Cardiology. 2018;14(5):774–784. (In Russ.). DOI: https://doi.org/10.20996/1819-6446-2018-14-5-774-784.
3. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–968. DOI: https://doi.org/10.1001/jama.2013.184182.
4. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). DOI: https://doi.org/10.15829/1560-4071-2020-3-3786.
5. Shalnova SA, Deev AD, Balanova YuA, Zhernakova YuV, Kondratii AO, Boytsov SA, et al. Treatment of hypertension in high-risk patients. Monotherapy or combination? Lechaschi Vrach. 2016;(7):17. (In Russ.). EDN: https://elibrary.ru/WMOCBD.
6. Chazova IE, Zhernakova YuV on behalf of the expert. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic Hypertensions. 2019;16(1):6–31. (In Russ.). EDN: https://www.elibrary.ru/aezoan.
7. Kolomijecs PN. “Silver economics” a new approach to the problem of aging. Journal of Economic Regulation. 2018;9(1):89–101. (In Russ.). DOI: https://doi.org/10.17835/2078-5429.2018.9.1.089-101.
8. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics — 2015 update: A report from the American Heart Association. Circulation. 2015;131(4):29–322. DOI: https://doi.org/10.1161/CIR.0000000000000152.
9. Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. World Journal of Cardiology. 2012;4(5):135–147. DOI: https://doi.org/10.4330/wjc.v4.i5.135.
10. Anatskaya LN. Features of ischemic stroke in older people. Meditsinskie novosti. 2011;1(1):10–12. (In. Russ.). EDN: https://elibrary.ru/OGBAOJ.
11. Chesnikova AI, Batyushin MM, Terentyev VP. Arterial hypertension and comorbidity: State of the art. Arterial Hypertension. 2016;22 (5):432–440. (In Russ.). DOI: https://doi.org/10.18705/1607-419X-2016-22-5-432-440.
12. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovascular Pathology. 2012;21(5):365–371. DOI: https://doi.org/10.1016/j.carpath.2011.11.007.
13. Pizova NV. Ischemic stroke and age. Polyclinic. 2023;(3–2):49–52. (In Russ.). EDN: https://elibrary.ru/BNBDSK.
14. Konstantinova EV, Balayan NM, Shostak NA. Myocardial infarction in young patients: Causes and prognosis. The Clinician. 2017;11(1):10–15. (In Russ.). DOI: https://doi.org/10.17650/1818-8338-2016-10-4-10-15.
15. Kabalyk MA. The features of cytokine status in patients with osteoarthritis and essential hypertension. The Bulletin of Contemporary Clinical Medicine. 2017;10(3):10–15. (In Russ.). DOI: https://doi.org/10.20969/VSKM.2017.10(3).10–15.
16. Hawker GA, Croxford R, Bierman AS, Harvey PJ, Ravi B, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: A population based cohort study. PLoS ONE. 2014; 9(3):e91286. DOI: https://doi.org/10.1371/journal.pone.0091286.
17. Alekseeva LI, Naumov AV. Management of comorbid osteoarthritis: Clinical recommendations for general practitioners. Doctor.Ru. 2017;(5):51–69. (In Russ.). EDN: https://elibrary.ru/YPQCAR.
18. Leganova NM, Nechaeva GI. Combined therapy of patients with arterial hypertension in combination with osteoarthritis: Effect on hemodynamics. Siberian Medical Journal. 2011;100(1):98–100. (In Russ). EDN: https://elibrary.ru/NQVINX.
19. Peshekhonova LK, Krasyukov PA. Combined therapy of osteoarthritis in comorbid patients suffering from arterial hypertension. In: Arterial hypertension: From theory to practice. Kemerovo: LLC “InterMedservice”; 2015. P. 38. (In Russ). EDN: https://elibrary.ru/TQHXUJ.
20. Grigorieva IN, RaginoYuI, Romanova TI. Epidemiology and comorbidity of arterial hypertension and gallstone disease. Russian Journal of Cardiology. 2019;(6):143–148. (In Russ). DOI: https://doi.org/10.15829/1560-4071-2019-6-143-148.
21. Daugherty SL, Masoudi F, Ellis JL, Ho PM, Schmittdiel JA, Tavel H M, et al. Age dependent gender differences in hypertension management. Journal of Hypertension. 2011;29(5):1005–1011. DOI: https://doi.org/10.1097/HJH.0b013e3283449512.
22. Karpov YuA. Novel 2010 recommendations on arterial hypertension of RMSAH/RSSC: Combination therapy issues. Russian Medical Journal. 2010;18(22):1290–1297. (In Russ.). EDN: https://elibrary.ru/PRNPDV.
23. Lukina YuV, Martsevich SYu. Combined therapy of arterial hypertension is a reliable way to achieve the goal. Rational Pharmacotherapy in Cardiology. 2010;6(6):859–864. (In Russ). DOI: https://doi.org/10.20996/1819-6446-2010-6-6-859-864.
24. Graham ID, Atar D, Borch-Johnsen K, Borch-Johnsen K, Boysen G, Burell G, et al. European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation. 2007;14 Suppl 2:S1–S113. DOI: https://doi.org/10.1097/01.hjr.0000277983.23934.c9.
25. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. The Lancet. 2005;366(9489):895–906. DOI: https://doi.org/10.1016/s0140-6736(05)67185-1.
26. Averin EE, Nikitin AE, Nikitin IG, Sozykin AV. New European guidelines for hypertension: An emphasis on combination therapy. Medical Alphabet. 2018;4(37):5–11. (In Russ). EDN: https://elibrary.ru/YYCBNJ.
27. Nambi V, Ballantyne CM. ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Current Atherosclerosis Reports. 2004;6(5):353–358. DOI: https://doi.org/10.1007/s11883-004-0046-1.
28. Gorokhova TV, Perepech NB. Potential of combination therapy in patients with hypertension and dyslipidemia. Russian Journal of Cardiology. 2022;27(7):5132. (In Russ.). DOI: https://doi.org/10.15829/1560-4071-2022-5132.
29. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal. 2006;27(24):2982–2988. DOI: https://doi.org/10.1093/eurheartj/ehl403.
30. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. The New English Journal of Medicine. 2016:374(21):2021–2031. DOI: https://doi.org/10.1056/NEJMoa1600176.
31. Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.). DOI: https://doi.org/10.15829/1560-4071-2023-5471.
32. Diagnosis and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian guidelines. VII revision. Journal of Atherosclerosis and Dyslipidaemias. 2020;(38):7–40. (In Russ.). DOI: https://doi.org/10.34687/2219-8202.JAD.2020.01.0002.
33. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459–2472. DOI: https://doi.org/10.1093/eurheartj/ehx144.
34. Karpov YuA. The role of statins in prevention of cardiovascular diseases in real clinical practice. Doctor.Ru. 2021;20(11):17–27. (In Russ.). DOI: https://doi.org/10.31550/1727-2378-2021-20-11-17-27.
35. Malay LN. Statins in the treatment and prevention of cardiovascular diseases: Repetition of the past and optimism for the future. Rational Pharmacotherapy in Cardiology. 2014;10(5):513–524. (In Russ.). DOI: https://doi.org/10.20996/1819-6446-2014-10-5-513-524.
36. Vijayaraghavan K, Baum S, Desai NR, Voyce SJ. Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins. Frontiers in Cardiovascular Medicine. 2024;10:1308173. DOI: https://doi.org/10.3389/fcvm.2023.1308173.
37. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. The Lancet. 2014;383(9932):1899–1911. DOI: https://doi.org/10.1016/S0140-6736(14)60685-1.
38. Odebaeva R, Achkasov EE, Shurgaya MA. Features of the structure of adult disability due to hypertension. Medical and Social Expert Evaluation and Rehabilitation. 2020;23(2):46–51. (In Russ.). DOI: https://doi.org/10.17816/MSER44244.
Supplementary files
Review
For citations:
Izmozherova NV, Popov AA, Kuryndina AA, Gavrilova EI, Shambatov MA, Bakhtin VM. Analysis of Pharmacotherapy of Arterial Hypertension in Multimorbid Patients. Ural Medical Journal. 2025;24(1):7–25. (In Russ.) https://doi.org/10.52420/umj.24.1.7. EDN: BOTFNT
Views:
237
Email this article 